University of California
Welcome,         Profile    Billing    Logout  
 1 Trial 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Budoff, Matthew
EKSTROM, NCT06342609: Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease

Completed
4
84
US
Colchicine 0.5 MG, Mitigare, Colcrys
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Coronary Artery Disease
09/24
09/24
WARRIOR, NCT03417388: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Active, not recruiting
4
2476
US
High dose potent statin, atorvastatin or rosuvastatin, ACE-I (lisinopril) or ARB (losartan), ACE-I or ARB, Aspirin, Lifestyle Counseling, PACE Lifestyle Intervention, Quality of Life Questionnaires, QOL
University of Florida, United States Department of Defense
Coronary Artery Disease
02/25
09/25
T-PLAQUE, NCT05708859: Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Recruiting
4
120
US
Tirzepatide, Mounjaro, Placebo
Matthew J. Budoff, Eli Lilly and Company
Type II Diabetes, Atherosclerosis
12/25
05/26
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Active, not recruiting
3
608
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Coronary Artery Disease
01/27
01/27
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Keto-CTA, NCT05733325: Diet-induced Elevations in LDL-C and Progression of Atherosclerosis

Completed
N/A
100
US
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Citizen Science Foundation
Hypercholesterolemia
02/24
02/24

Download Options